NextCell Pharma AB (SE:NXTCL)

:NXTCL

NXTCL

NextCell Pharma AB

RESEARCH TOOLSreports

Want to see SE:NXTCL full AI Analyst Report?

NextCell Pharma AB (NXTCL) Price & Analysis

1 Followers

NXTCL Stock Chart & Stats

kr0.92

kr0.02(0.56%)

At close: Mar 06 4:00 PM EST

kr0.92

kr0.02(0.56%)

Day’s Range― - ―

52-Week Rangekr0.63 - kr1.78

Previous CloseN/A

Volume77.06K

Average Volume (3M)237.08K

Market Cap

kr127.88M

Enterprise Valuekr101.85M

Total Cash (Recent Filing)kr26.03M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.32

Next Earnings

May 28, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.08

Shares Outstanding111,392,960

10 Day Avg. Volume155,192

30 Day Avg. Volume237,081

Financial Highlights & Ratios

PEG Ratio0.13

Price to Book (P/B)1.36

Price to Sales (P/S)8.24

P/FCF Ratio-2.09

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.4

Revenue Forecast (FY)kr13.90M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetA debt-free capital structure materially reduces refinancing and interest-rate risk for a cash-burning biotech. This structural strength preserves flexibility to raise equity or partner non-dilutive financing, helping sustain R&D programs and clinical timelines over the next 2–6 months without imminent debt pressure.

Focused Cell-therapy PlatformA concentrated platform around MSC-based cell therapies provides durable strategic clarity and potential for deep technical expertise and IP build-up. This specialization aligns the company with expanding regenerative-medicine demand and supports sustained clinical development and partner interest over the medium term.

Lean Operating StructureA very small headcount implies a lean cost base that can extend runway and focus spend on core R&D activities. Structurally, low fixed overhead supports flexibility in resource allocation, enabling the company to prioritize pivotal trials or partnerships without large incremental SG&A burdens.

Bears Say

Persistent Cash BurnSustained negative operating and free cash flows are a structural vulnerability: the business requires continual external financing to fund operations and trials. Over several months this elevates dilution and financing execution risk, potentially disrupting clinical programs or slowing development timelines if capital access tightens.

Negative Gross Profit And MarginsNegative gross profit means current costs exceed revenues, indicating the core model isn't yet scaling sustainably. Deep operating and net losses create a structural need to either materially grow revenue or cut costs; absent that, profitability remains distant and investor dependence on recurring funding persists.

Eroding Equity BaseA sharply reduced equity cushion lowers the company's financial buffer, increasing vulnerability to shocks and making future capital raises more dilutive or costly. Structurally this heightens funding risk for ongoing trials and may constrain strategic optionality over the medium term unless operating losses reverse.

NXTCL FAQ

What was NextCell Pharma AB’s price range in the past 12 months?

NextCell Pharma AB lowest stock price was kr0.63 and its highest was kr1.78 in the past 12 months.

What is NextCell Pharma AB’s market cap?

NextCell Pharma AB’s market cap is kr127.88M.

When is NextCell Pharma AB’s upcoming earnings report date?

NextCell Pharma AB’s upcoming earnings report date is May 28, 2026 which is in 28 days.

How were NextCell Pharma AB’s earnings last quarter?

NextCell Pharma AB released its earnings results on Oct 30, 2025. The company reported -kr0.079 earnings per share for the quarter, beating the consensus estimate of -kr0.1 by kr0.021.

Is NextCell Pharma AB overvalued?

According to Wall Street analysts NextCell Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NextCell Pharma AB pay dividends?

NextCell Pharma AB does not currently pay dividends.

What is NextCell Pharma AB’s EPS estimate?

NextCell Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NextCell Pharma AB have?

NextCell Pharma AB has 111,392,960 shares outstanding.

What happened to NextCell Pharma AB’s price movement after its last earnings report?

NextCell Pharma AB reported an EPS of -kr0.079 in its last earnings report, beating expectations of -kr0.1. Following the earnings report the stock price went up 0.787%.

Which hedge fund is a major shareholder of NextCell Pharma AB?

Currently, no hedge funds are holding shares in SE:NXTCL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NextCell Pharma AB

NextCell Pharma AB (NXTCL) is a Swedish biopharmaceutical company focused on the development and commercialization of advanced therapies for immune-related diseases. The company specializes in stem cell-based treatments, with its flagship product, ProTrans, developed for the treatment of autoimmune conditions such as Type 1 Diabetes. NextCell Pharma operates within the biotechnology and healthcare sectors, aiming to leverage cutting-edge research to provide innovative therapeutic solutions.